PureHealth shareholders approve AED 600 million dividend after strong FY2025 results

PureHealth shareholders approved an AED 600 million dividend at the company's annual general meeting, the largest cash distribution from a UAE-listed healthcare group in FY2025.

The dividend marks continued returns from a group that spent the past three years on an aggressive acquisition-and-integration cycle. For investors tracking healthcare on the Abu Dhabi Securities Exchange (ADX), the payout signals that PureHealth's consolidation strategy now generates consistent free cash flow, not just top-line growth.

What the numbers mean for UAE healthcare

PureHealth operates more than 100 healthcare assets across hospitals, clinics, pharmacies, diagnostics labs, and health insurance. The group is the single largest private-sector healthcare employer in the country. Its portfolio includes Burjeel Holdings, ADNOC Medical, and stakes across the ambulatory and post-acute care spectrum.

An AED 600 million dividend from a company of this scale carries two readings. For PureHealth's institutional shareholders, including ADQ (the Abu Dhabi sovereign wealth fund that remains the controlling stakeholder), it confirms that vertical integration across the care continuum can produce returns comparable to pure-play hospital operators. For competing healthcare groups, it sets a new benchmark on what public-market investors expect from listed UAE health platforms.

The payout comes as the Department of Health Abu Dhabi (DOH) continues to push its Daman insurance reform and mandatory health coverage expansion. Those policies have driven volume growth across Abu Dhabi's provider network. PureHealth, with facilities concentrated in Abu Dhabi and Al Ain, is a direct beneficiary of rising insured-patient volumes.

Competitive pressure builds

PureHealth's dividend announcement arrives in a crowded field. Burjeel Holdings, which listed on ADX in October 2023, has its own growth trajectory to defend. Mediclinic Middle East continues to expand its Abu Dhabi and Dubai footprint. In Dubai, the Dubai Health Authority (DHA) licensed more than 4,200 active healthcare facilities as of late 2025, and competition for outpatient volumes has intensified.

For CFOs at mid-sized UAE hospital groups, PureHealth's ability to invest in expansion and return AED 600 million to shareholders at the same time creates a benchmarking problem. Boards will ask why their group cannot do both. The answer, in most cases, is scale: PureHealth's integrated model spreads fixed costs across diagnostics, insurance, pharmacy, and acute care in a way that standalone operators cannot replicate without their own M&A activity.

What to watch next

Four questions will shape PureHealth's trajectory over the next two quarters:

• Whether PureHealth increases its stake in Burjeel Holdings or pursues further consolidation in the Northern Emirates, where MOHAP-regulated facilities remain fragmented
• How DOH's updated pricing framework for 2026–2027 affects margins across Abu Dhabi providers, PureHealth included
• Whether PureHealth accelerates health-tech investments, particularly in AI-assisted diagnostics and electronic health record interoperability, where DOH has signaled new regulatory requirements
• How the group absorbs an estimated 1.5 million new UAE residents added in the past two years into its patient funnel across primary and specialty care

The dividend vote is settled. The harder question for the UAE healthcare sector: whether PureHealth's scale advantage is now self-reinforcing, or whether smaller operators still have room to compete on specialization and patient experience.